DA
NRIX icon

Denali Advisors’s Nurix Therapeutics NRIX Stock Holding History

Denali Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-57,500
Closed -$593K – 482
2023
Q4 		$593K Buy
+57,500
New +$394K 0.18% 122
2023
Q1 		– Sell
-5,900
Closed -$64.8K – 478
2022
Q4 		$64.8K Buy
5,900
+2,300
+64% +$27.7K 0.03% 199
2022
Q3 		$47K Buy
+3,600
New +$57K 0.02% 218

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Denali Advisors's NRIX Position: Q1 2024 in Review

Denali Advisors sold out of Nurix Therapeutics (NRIX) in Q1 2024, closing a stake of 57,500 shares — an estimated $593K sold.

Denali Advisors first reported a position in NRIX in Q3 2022 and held it in 3 quarters. The position peaked at $593K in Q4 2023. 139 funds tracked by Wall St. Rank hold NRIX as of Q1 2024.

  • Denali Advisors reported no remaining Nurix Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Denali Advisors sold 57,500 Nurix Therapeutics shares in Q1 2024, an estimated $593K.
  • Denali Advisors first reported a position in Nurix Therapeutics in Q3 2022 and held it in 3 quarters.
  • Denali Advisors's Nurix Therapeutics position peaked at $593K in Q4 2023.
  • 139 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2024.

Based on Denali Advisors's 13F filing for Q1 2024, filed 19 Apr 2024.